Want to see PLSE full AI Analyst Report?
PLSE Stock Chart & Stats
$48.10
$2.56(8.47%)
At close: 4:00 PM EDT
$48.10
$2.56(8.47%)
Day’s Range― - ―
52-Week Range$12.56 - $58.90
Previous Close$32.94
Volume432.45K
Average Volume (3M)585.02K
Market Cap
$3.84B
Enterprise Value$1.82K
Total Cash (Recent Filing)$101.62M
Total Debt (Recent Filing)$6.77M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Nov 16, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding71,322,610
10 Day Avg. Volume736,493
30 Day Avg. Volume585,023
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)11.47
Price to Sales (P/S)2643.82
P/FCF Ratio-17.00
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$50.80Price Target Upside5.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.21
Revenue Forecast (FY)$2.39M
Bulls Say, Bears Say
Bulls Say
Accelerated Clinical EnrollmentAccelerated enrollment supports execution credibility for Pulse Biosciences’ flagship cardiac program and may shorten the path to pivotal data. Faster progress can improve resource efficiency, strengthen physician and investigator engagement, and advance the company’s competitive position in atrial fibrillation ablation.
Promising Clinical Efficacy And SafetyStrong feasibility outcomes provide important clinical validation for the nsPFA platform, particularly if durability and safety are confirmed in pivotal studies. Such evidence can support regulatory submissions, physician adoption, and broader expansion across cardiac and other soft-tissue indications.
Strengthened Liquidity And Low LeverageA sizable equity base and low leverage give Pulse Biosciences more flexibility to fund clinical development without relying heavily on debt. Combined with reported cash resources, this reduces near-term balance-sheet pressure while the company works toward regulatory and commercial milestones.
Bears Say
Very Small Commercial RevenueThe company remains at an early commercialization stage, with revenue too small to absorb its development infrastructure and operating costs. Even strong percentage growth starts from a limited base, so meaningful operating leverage and a self-sustaining commercial model remain unproven over the next several quarters.
Large Ongoing Cash BurnPersistent cash outflows show that reported losses are translating into substantial funding needs rather than being primarily non-cash accounting effects. Continued clinical investment may advance the pipeline, but the scale of burn can constrain flexibility and require additional capital before profitability is reached.
Regulatory Timeline RiskRapid enrollment does not eliminate the need to complete lengthy follow-up periods before definitive regulatory submissions can progress. This creates a structural timing dependency for the cardiac program, potentially delaying approval, commercialization, and the point at which clinical investment can translate into meaningful revenue.
Pulse Biosciences News
PLSE FAQ
What was Pulse Biosciences’s price range in the past 12 months?
Pulse Biosciences lowest stock price was $12.56 and its highest was $58.90 in the past 12 months.
What is Pulse Biosciences’s market cap?
Pulse Biosciences’s market cap is $3.84B.
When is Pulse Biosciences’s upcoming earnings report date?
Pulse Biosciences’s upcoming earnings report date is Nov 16, 2026 which is in 55 days.
How were Pulse Biosciences’s earnings last quarter?
Pulse Biosciences released its earnings results on Aug 06, 2026. The company reported -$0.284 earnings per share for the quarter, beating the consensus estimate of -$0.31 by $0.026.
Is Pulse Biosciences overvalued?
According to Wall Street analysts Pulse Biosciences’s price is currently Undervalued.
Does Pulse Biosciences pay dividends?
Pulse Biosciences does not currently pay dividends.
What is Pulse Biosciences’s EPS estimate?
Pulse Biosciences’s EPS estimate is -0.32.
How many shares outstanding does Pulse Biosciences have?
Pulse Biosciences has 71,322,610 shares outstanding.
What happened to Pulse Biosciences’s price movement after its last earnings report?
Pulse Biosciences reported an EPS of -$0.284 in its last earnings report, beating expectations of -$0.31. Following the earnings report the stock price went up 10.905%.
Which hedge fund is a major shareholder of Pulse Biosciences?
Currently, no hedge funds are holding shares in PLSE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pulse Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.80 (5.61% Upside)
$50.80 (5.61% Upside)
Blogger Sentiment
Bullish
PLSE Sentiment 88%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Decreased
By 12.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $199.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
190.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pulse Biosciences
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
PLSE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong, positive clinical momentum and operational progress: accelerated pivotal enrollment, compelling EU feasibility efficacy and safety data, procedural efficiency that suggests meaningful hospital economics, strengthened leadership, and a materially improved cash position following ATM proceeds. These positives are balanced by early-stage commercial revenue that remains small, rising operating expenses and widening losses driven by increased clinical investment, ongoing cash burn, and continued dependence on capital markets. Regulatory timing still depends on 12-month follow-up for earlier enrollees, creating a measurable timeline risk. On balance, the highlights — particularly the rapid enrollment, robust feasibility outcomes, and strengthened balance sheet — outweigh the lowlights.View all PLSE earnings summariesPLSE Stock 12 Month Forecast
Average Price Target
$50.80
▲(5.61% Upside)
Technical Analysis
Ownership Overview
70.86% Insiders
2.19% Mutual Funds
1.86% Other Institutional Investors
22.04% Public Companies and
Individual Investors